HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Talaris Therapeutics (NASDAQ:TALS) with a Buy and maintains $12 price target.
Wells Fargo Maintains Equal-Weight on L3Harris Technologies, Raises Price Target to $230
Wells Fargo analyst Matthew Akers maintains L3Harris Technologies (NYSE:LHX) with a Equal-Weight and raises the price target from $219 to $230.